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A B S T R A C T
Aim: PANcreatic-DERived factor (PANDER, FAM3B) is a novel hormone that regulates glucose levels via in-
teraction with both the endocrine pancreas and liver. Prior studies examining PANDER were primarily con-
ducted in murine models or in vitro but little is known regarding the circulating concentration of PANDER in
humans, especially with regard to the association of type 2 diabetes (T2D) or overall glycemic regulation. To
address this limitation, we performed a cross-sectional analysis of circulating serum PANDER concentration in
association with other hormones that serve as either markers of insulin resistance (insulin and adiponectin) or to
metabolic parameters of glycemic control such as fasting HbA1c and blood glucose (FBG).
Methods: Fasting serum was obtained from a commercial biorepository from 300 de-identified adult subjects
with 150 T2D and non-T2D adult subjects collected from a population within the United States, respectively,
matched on gender, age group and race/ethnicity. Concentration of PANDER, insulin and adiponectin were
measured for all samples as determined by commercial ELISA. Metadata was provided for each subject including
demography, anthropometry, and cigarette and alcohol use. In addition, fasting blood glucose (FBG) and HbA1c
were available on T2D subjects.
Results: Multiple linear regression analyses were performed to examine the relationships between circulating log
PANDER concentration on HbA1c, fasting glucose, log insulin, log HOMA-β and log HOMA-IR among T2D
subjects and for insulin and adiponectin in non-T2D subjects. A significant linear association was identified
between PANDER with fasting HbA1c (β 0.832 ± SE 0.22, p= 0.0003) and FBG (β 20.66 ± SE 7.43,
p= 0.006) within T2D subjects. However, insulin, HOMA-β, HOMA-IR and adiponectin (p > 0.05) were not
found to be linearly associated with PANDER concentration.
Conclusion: Within T2D subjects, PANDER is modestly linearly associated with increased HbA1c and FBG in a US
population. In addition, highest circulating PANDER levels were measured in T2D subjects with HbA1c above
9.9. No association was identified with PANDER and insulin resistance or pancreatic β-cell function in T2D
subjects.
Introduction
PANDER (PANcreatic-DERived factor or FAM3B) is a member
within the family with sequence similarity 3 (FAM3) super family [1].
This secreted protein is comprised of 235 amino acids and is strongly
expressed from the endocrine pancreas [2]. The initial discovery of
PANDER was the result of a computational algorithm, ostensible re-
cognition of folds (ORF), in an attempt to identify novel cytokines based
on a predicted secondary structure of a four-helix bundle common to
many cytokines [1]. From ORF, the four members of this family with
sequence similarity 3 were identified, FAM3A-FAM3D, respectively. All
members of the FAM3 family have 224–235 amino acids, including four
conserved cysteines with a secretion signal sequence. FAM3B was later
named PANcreatic-DERived factor (PANDER) in 2003 due to dominant
expression in the endocrine pancreas [2]. Localization of PANDER to
insulin granules within pancreatic β-cells revealed PANDER is co-se-
creted with insulin in response to glucose [3].
The PANDER receptor is currently unknown. However, iodinated
binding studies revealed the liver is a target tissue [4]. A plethora of
publications reporting various biological aspects of PANDER have ex-
amined numerous animal models (reviewed in [5–7]). In summary,
these studies indicated a hormonal biological role for PANDER for
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regulation of glycemic levels. Mechanism of PANDER action is through
the regulation of hepatic insulin signaling and insulin secretion from
the endocrine pancreas. Increased expression of circulating PANDER
induces insulin resistance in murine models [8]. Concordantly,
PANDER knockout models have increased hepatic insulin sensitivity
and are resistant to high fat diet induced fasting hyperglycemia and
hyperinsulinemia [9,10]. Of clinical importance with regard to T2D is
the demonstration that PANDER can induce selective hepatic insulin
resistance. This differential signaling results in a metabolic state that
mimics what is observed in T2D animal models and humans whereby
gluconeogenesis and hepatic lipogenesis are both increased [11,12].
Taken together, earlier evidence suggests that PANDER may serve as an
etiological hormone during pathophysiological conditions driving se-
lective hepatic insulin resistance (SHIR) within T2D [13].
One of the major gaps in understanding PANDER’s biological role
and involvement with the pathogenesis of T2D is with regard to the
circulating concentration in humans in association with glucose intol-
erance and the primary clinical measurement of glycemic control,
HbA1c. At present, two reports have examined circulating PANDER
concentration in association with metabolic syndrome and pancreatic
β-cell dysfunction, however none have focused on the relationship of
PANDER with glycemic control specifically within T2D subjects
[14,15]. Therefore, this limited clinical and physiological in vivo data
presents a major limitation in the biological understanding of PANDER
within T2D. To address this, we have performed a cross-sectional
analysis of circulating PANDER concentration in the serum of 150 T2D
subjects and matched non-T2D subjects in association with diabetes
status, insulin and adiponectin in all subjects. Within T2D subjects, we
examined the association of PANDER and fasting blood glucose (FBG),
HbA1c, HOMA-β (measures of pancreatic β-cell function) and HOMA-IR
(measure of insulin resistance).
Materials & methods
Participants and clinical information
Fasting serum samples from 300 (150 T2D and 150 non-T2D) sub-
jects in combination with recorded metadata was obtained from a
commercial biobank (BioServe Biotechnologies, Ltd). Comprehensive,
de-identified, covariate data such as age, gender, race, anthropometric
measures such as body mass index (BMI), and cigarette and alcohol use
were provided. Subjects were matched on age, gender and race/ethni-
city. For age, 145 were matched to a control subject within± 5 years,
and 4 were matched within±9 years. Due to limited availability of
control subjects among minority groups, one T2D subject was matched
to a control subject that was 13 years younger. Subject information and
biospecimens were collected using IRB approved Consent Forms and
Collections Protocols as described by BioServe Biotechnologies (www.
bioserve.com). No identifying information was provided with the
samples or the corresponding metadata. Study was determined as re-
search exempt since samples were obtained from a de-identified com-
mercial repository. The key between the BioServe ID and the patient
HIPAA protected information is currently housed at the clinic of sample
origin. Whole blood and serum were collected at time of visit and sent
to Quest Diagnostics™ for measurement of HbA1c and fasting blood
glucose, respectively. Additional serum aliquots were also obtained and
immediately stored upon collection. All of the subjects in the Type 2
diabetes collection were identified through one of the IRB approved
endocrinologists using data and sample collection protocols that have
undergone IRB review. The eligibility criteria are listed below consisted
of the following: (1) Patient has been diagnosed with Type II Diabetes,
(2) Patient had a previous fasting glucose> 126mg on two occasions
or post-prandial glucose of> 200mg/dl on one prior occasion, Patient
is non-pregnant female or male> 18 years of age, (3) Patient has suf-
ficient understanding to agree to the study activities, (4) Patient has
physician’s permission to participate and (5) Patient must not be related
(by first degree) to any other study subjects. Our non-T2D group con-
sisted of healthy subjects coming in for routine well-visits. The non-T2D
group was initially screened using case report forms and questioned for
presence of disease for three generations (on both sides of the family)
for health history including diabetes, cancer, etc. These controls were
used as healthy controls for a number of different types of studies based
upon the extensive screening by the clinical studies nurses or a clinical
research associate, and the case report form questions. Most samples
were collected in 2000 or 2001 and stored at −70 °C since moment of
collection. Freezers (maintained by Bioserve) were monitored electro-
nically continuously, and checked once a day, manually, 365 days a
year. All samples were collected using approved IRB protocols and
stored in a CLIA approved laboratory.
PANDER, insulin and adiponectin measurements
Approximately 500 µl to 1ml of serum was received from each
subject from BioServe and stored at −80 °C prior to examination of
PANDER, insulin and adiponectin concentration as determined by
commercial ELISAs. Following receipt of serum samples, aliquots were
compiled to ensure no variation in freeze/thaw exposure. PANDER
concentration were examined in 100 µl of serum in duplicate following
manufacturer’s instructions using the Human Pancreatic Derived
Factor/FAM3B Antibody ELISA Kit (Catalog number E01P0025, Life
Sciences Advanced Technologies, Inc.) with a reported sensitivity in
this assay of 0.1 ng/mL and range of 0.5 to 20 ng/ml. Insulin levels were
measured in 25 µl of serum in duplicate following manufacturer’s in-
structions using the Ultrasensitive Insulin ELISA Kit (Catalog number
80-INSHUU-E10, ALPCO) with a reported sensitivity of 0.135 µIU/mL
and range of 0.15–20 µIU/mL. Adiponectin levels were determined in 5
µl of serum in duplicate following manufacturer’s instructions using the
STELLUX® Chemi Human Total Adiponectin ELISA (Catalog number 80-
ADPHUT-CH01, ALPCO) with a reported sensitivity of 0.08 ng/mL and
range of 0.066–68.09 ng/mL.
Homeostatic model assessment
The homeostatic model assessment (HOMA) was utilized to measure
both pancreatic β-cell function (HOMA-β) and insulin resistance
(HOMA-IR). HOMA-β was calculated using the following formula:
[360*fastinginsulin(μU/mL)/fastingglucose]− 63. HOMA-IR was de-
termined by the following formula: [fasting glucose (mg/dL)∗fasting
insulin (μU/mL)]/405. Due to the lack of availability of fasting mea-
sures of glucose for non-T2D subjects, HOMA-β and HOMA-IR were
calculated only for T2D subjects.
Statistical analysis
Data are presented as means and standard deviations for continuous
variables and as the number of subjects and percent for categorical
data. Distributions of the PANDER, insulin, adiponectin, HOMA-β,
HOMA-IR and hormonal concentrations were found to be skewed and
were log transformed for all analyses. For these variables, the data are
presented as the geometric mean and interquartile range. Due to the
small number of minority subjects, race/ethnicity was categorized as
white and other. Cigarette smoking status was defined as current,
former, and never. Alcohol use was defined as any self-reported current
alcohol use (> 0 drinks per week or day). Exploratory and descriptive
analyses were performed to examine the distributions of variables and
identify bivariate associations using distribution appropriate statistical
tests (e.g., t-test, Wilcoxon Rank-Sum, chi-square, etc.).
Separate linear regression models were constructed with HbA1c,
FBG, insulin, adiponectin, HOMA-B and HOMA-IR as the dependent
variables and log PANDER as the main independent variable of interest.
The β and standard error (SE) for log PANDER is presented from un-
adjusted models and models adjusted for age, gender, race/ethnicity,
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duration of diabetes, and BMI. Additional covariates that were tested
and not retained in the models were cigarette status and alcohol use
since inclusion of these in the models did not meaningfully alter the
estimate of association between PANDER and any of the dependent
variables. As FBG and HbA1c was not available for non-T2D subjects,
these analyses were restricted to T2D subjects. Linear regression ana-
lyses was also performed for insulin and adiponectin separately in those
with and without diabetes. All statistical analyses were performed using
SAS 9.4 (SAS Institute Inc., Cary, NC).
Results
Study design
The overall characteristics of the subject population are shown in
Table 1. The mean age of subjects in this study population was ap-
proximately 60 years. The study population had slightly more males
than females (52% vs 48%) and was predominantly Caucasian (71.3%).
Current cigarette and alcohol use was higher in the non-T2D group
(P≤ 0.002). BMI was higher among those with T2D (32.6 ± 7.4 vs
25.2 ± 6.6, P < 0.001). Mean duration of T2D was 7 years, with a
mean HbA1c of 8.3 (± 2.2) and a mean FBG of 169.0 (± 72.6). No
significant differences were identified between the groups for insulin
and PANDER. However, adiponectin was significantly lower among
those with T2D (16.4 vs. 18.5, P < 0.05) as expected since decreased
adiponectin levels are associated with insulin resistance.
Multiple linear regression models
Table 2 presents the results of the multiple linear regression models
of log PANDER on HbA1c, FBG, log insulin, log HOMA-β, log HOMA-IR
adjusted for age, gender, race, BMI, and duration of diabetes (un-
adjusted are also shown). In this model, a significant linear association
was identified between PANDER with HbA1c (β 0.75 ± 0.23,
P= 0.002) and FBG (β 20.4 ± 7.7, P=0.010). Log insulin, log
HOMA-β, log HOMA-IR, and adiponectin were not found to be linearly
associated with PANDER concentration (p > 0.05). In addition, further
linear regression analysis was performed evaluating the controls and
T2D subjects separately for the adiponectin and insulin regressions.
There was no association between adiponectin and PANDER in controls,
and the interaction term by diabetes status was not significant (data not
shown). However, in the non-T2D subjects, PANDER is significantly
negatively associated with insulin (β −0.22 ± 0.11, p=0.044) and
the interaction term by diabetes status reached near significance
(p= 0.079).
Serum PANDER concentration in association with HbA1c
To further examine the associations of PANDER with long term
glucose intolerance, least squares adjusted means of PANDER were
examined by quartiles of HbA1c within T2D subjects. Increased
PANDER concentration were significantly associated with increased
HbA1c quartile ranges within the T2D group (1st quartile 352.4 pg/ml
vs 4th quartile 762.9 pg /ml, P=0.0085) (Fig. 1).
Discussion
This study indicates that increased circulating PANDER
Table 1
Subject Characteristics.
Characteristic T2D N=150 Non-T2D N=150 p-value
Age (years)* 60.7 ± 12.6 60.3 ± 12.5
Male (n)† 78 (52.0) 78 (52.0)
Race/ethnicity (n) †
White 107 (71.3) 107 (71.3)
Other 43 (28.7) 43 (28.7)
Cigarettes (n)† 0.001
Current 17 (12.6) 44 (30.6)
Former 46 (34.1) 36 (25.0)
Never 72 (53.3) 64 (44.4)
Alcohol use (n)† 0.002
Yes 32 (21.5) 56 (37.6)
No 117 (78.5) 93 (62.4)
Duration of diabetes (years)‡ 7 (3–13) NA
BMI (kg/m2)* 32.6 ± 7.4 25.2 ± 6.6 < 0.001
HbA1c (%)* 8.3 ± 2.3 NA
Fasting blood glucose (mg/
dl)*
169.0 ± 72.6 NA
PANDER (ng/ml)§ 0.41 (0.33–0.64) 0.40 (0.28–0.62)
Insulin (μIU/ml)§ 12.0 (7.1–17.8) 10.7 (5.9–18.5)
Adiponectin (ng/ml)§ 16.4 (11.6–21.8) 18.5 (14.1–26.7) 0.048
HOMA-β§ 48.8 (24.0–85.3) NA
HOMA-IR§ 4.6 (2.5–7.0) NA
Types of T2D treatment
Su only 28 (18.7%) NA
Bi only 15 (10%)
TZ only 10 (6.7%)
I only 20 (13.3%)
Su/Bi/Tz/I Combination 68 (45.3%)
No Treatment 9 (6%)
*Data presented as mean ± SD, p-value from t-test
†Data presented as number (%), p-value from Chi-square test
‡Data presented as median (25th-75th percentile)
§Data presented as geometric mean (25th-75th percentile), p-value from t-test
Types of T2D treatment- Su – sulfonylurea, Bi – biguanides, TZ – Thiazolidinediones, I –
insulin, Su/Bi/TZD/I – combination therapy of 2 or more medications, N – No treatment.
Data presented as number (%),
Table 2
Linear regression models of log PANDER (independent) on HbA1c, fasting glucose, log
insulin, log HOMA-β, log HOMA-IR, and adiponectin (dependent) among T2D subjects.
Outcome (dependent
variable)
Unadjusted Adjusted*
β±SE p-value β±SE p-value
HbA1c 0.74 ± 0.24 0.002 0.75 ± 0.23 0.002
Fasting blood glucose 17.8 ± 7.7 0.023 20.4 ± 7.7 0.010
Log Insulin 0.03 ± 0.09 0.728 0.05 ± 0.09 0.564
Log HOMA-β −0.15 ± 0.11 0.190 −0.15 ± 0.12 0.226
Log HOMA-IR 0.12 ± 0.10 0.232 0.16 ± 0.10 0.127
Adiponectin 0.02 ± 0.06 0.797 −0.001 ± 0.06 0.987
* Adjusted for age, sex, race, BMI, and duration of diabetes. Models are separate
models with HbA1c, fasting blood glucose, log insulin, log HOMA-β, log HOMA-IR, and
adiponectin as the dependent variables, respectively, and log PANDER as the independent
variable. β and standard error estimates presented are for log PANDER in unadjusted and
in adjusted models.
Fig. 1. Circulating PANDER concentration is associated with increased HbA1c.
Unadjusted means of PANDER by quartiles of HbA1c (n= 37–38 per quartile) are shown
in pg/ml. ** denotes P value < 0.01 as compared to 1st quartile.
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concentration is associated with elevated FBG and HbA1c among those
with T2D. This is one of the largest cross-sectional studies examining
the association of PANDER with measures of glycemic control among
those with T2D to show with linear regression that PANDER con-
centration is linearly associated with increased HbA1c and FBG.
Limited clinical data regarding circulating PANDER has inhibited the
complete understanding of this novel hormone’s involvement in the
onset or progression of T2D. In combination with prior PANDER animal
model data showing overexpression can promote fasting and fed glu-
cose intolerance [8,16], our results provide additional evidence for this
association. The primary source of the circulating PANDER is assumed
to be primarily derived from both pancreatic α and β-cells. PANDER is
found in high abundance within the endocrine pancreas with glucose
serving as a potent secretagogue [2,17]. Therefore, higher glucose le-
vels may increase PANDER secretion from the endocrine pancreas re-
sulting in increased circulating PANDER concentration. However,
PANDER is also strongly expressed and secreted from the liver with
glucose also serving as a potent PANDER secretagogue [16,18]. Taken
together, the origin of the circulating PANDER may be derived from
multiple organ sources including both the endocrine pancreas and the
liver. Increased circulating glucose concentration, as reflected by a
higher HbA1c, may indeed promote increased production and release
from multiple tissues such as pancreatic islets and hepatocytes. Other
tissues that have been shown to also produce PANDER (i.e. brain, sto-
mach and intestines) are most likely contributing to the increased
PANDER secretion modestly observed under high glucose conditions as
observed in our study but this may require further characterization.
Our findings are consistent in certain aspects with 2 other studies
examining circulating PANDER concentration [14,15]. Cao et al. pub-
lished that elevated circulating PANDER levels are associated with
metabolic syndrome in a Chinese population of 212 individuals be-
tween 40 and 65 years old [14]. In general, PANDER concentration
were positively associated with metabolic score, fasting plasma glucose,
and 2 h glucose. With regard to negative associations, PANDER con-
centration were inversely related to HOMA-β and high-density lipo-
protein cholesterol. Their study employed logistic regression analysis to
demonstrate that circulating PANDER was associated with an increased
odds ratio of impaired glucose tolerance or T2D following adjustment of
other cofounders. In addition, increased plasma PANDER concentration
were associated with dyslipidemia (high triglyceride concentration and
low HDL). Our previously published in vivo proteomic examination of
the PANDER transgenic model identified that hepatic lipogenesis was
the most strongly impacted biological process and strongly supports the
potential that increased PANDER concentration may be related to
dyslipidemia [19,20]. Unfortunately, levels of circulating triglycerides
or cholesterol were not measured or available for this study.
Shehata et al. examined circulating PANDER concentration to
evaluate the association of PANDER with impaired pancreatic β-cell
function in T2D [15]. In a cohort of 63 T2D subjects with varied clinical
duration, concentration of PANDER, proinsulin (PI), C-peptide and in-
sulin (I) were measured. Serum PANDER concentration was sig-
nificantly elevated in T2D subjects with longer disease duration.
However, this relationship was not identified in our study (Data not
shown, Spearman correlation (r)= 0.03 (p=0.69). Furthermore,
PANDER was negatively correlated to HOMA2-β and positively asso-
ciated with proinsulin, PI/I and PI/C-pep ratios. Comparing our results
to those earlier PANDER studies, we have also identified an association
with PANDER concentration and measures of glycemic control. Our
study failed to identify a significant relationship between PANDER and
HOMA-β as reported in the prior study. However, the differences in
PANDER associations found in our study versus others could be at-
tributed to variations in geographical collection sites as each in-
vestigation was performed either in China, Egypt or U.S, respectively.
Increased PANDER concentration has been demonstrated to pro-
mote hepatic insulin resistance in various animal models. However, this
relationship in humans has not been sufficiently examined. Adiponectin
is considered to be an insulin sensitizer with pleiotropic effects such as
suppression of hepatic gluconeogenesis, stimulation of fatty acid oxi-
dation, pancreatic β-cell insulin secretion, and skeletal muscle glucose
uptake [21]. Overall, adiponectin is negatively correlated with insulin
resistance with increased circulating concentration associated with a
lower risk of T2D [22,23]. The association of adiponectin with insulin
sensitivity justified our examination of this hormone in relation to
circulating PANDER. Although we observed the expected significant
decrease in adiponectin concentration in T2D as compared to non-T2D
subjects there was no measured association with PANDER concentra-
tion in either T2D or non-T2D subjects. Since only total adiponectin
levels were measured in this study this represents a potential limitation.
Adiponectin is initially expressed as a monomer of 28–30 kD that is
assembled in homooligomers of: low molecular weight trimeric form,
medium molecular weight hexameric, and high molecular weight
(HMW) [24]. HMW oligomers appear to be the major forms in insulin
sensitivity activities of adiponectin [25] and therefore future studies
examining the relationship of PANDER and adiponectin should include
measurements of the HMW form and lack of this measurement was a
limitation of our investigation.
A limitation of our study is the lack of HbA1c and FBG measure-
ments for our non-T2D group. Unfortunately, this prevented further
examination of PANDER concentration in association with glycemic
control within non-T2D subjects. There was no significant difference in
PANDER concentration between those with and without T2D in our
study. However, this may be attributed to several reasons. Based on our
HbA1c quartile examination, PANDER concentration appears to exhibit
a threshold effect where PANDER concentration is not significantly
increased until HbA1c is 9.9% or above. Since 50% of our T2D group
consisted of having a HbA1c of 7.6 or less, this may have confounded
the discrimination of PANDER concentration between the T2D and non-
T2D groups. Nonetheless, we still identified a very significant linear
relationship between PANDER and HbA1c within T2D subjects. Within
non-T2D subjects, an interesting association was observed in that
PANDER was negatively associated with insulin levels. This may be
explained biologically due to the differences between physiological and
pathophysiological conditions between non-T2D and T2D insulin re-
sistance. During normal physiological conditions (non-diabetic),
PANDER is mediating insulin action and promoting insulin clearance.
Our previous findings from the PANDER knockout model indicated that
hepatic insulin clearance is decreased during absence of PANDER [26].
If PANDER is regulating insulin clearance, this may explain why in-
creased PANDER is negatively associated with insulin levels in non-T2D
subjects but no association is found during insulin resistant conditions
when the action of PANDER may be inhibited.
In conclusion, PANDER is modestly associated with increased
HbA1c and FBG within T2D subjects particularly in those with un-
controlled hyperglycemia. Our limited findings did not provide evi-
dence to support that PANDER could serve as a useful biomarker for
insulin resistance or pancreatic β-cell function. Nonetheless, our results
do provide initial translational data regarding the fasting circulating
levels of PANDER in T2D subjects.
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